Recursion Pharmaceuticals (RXRX) director sells 30,000 shares in 10b5-1 plan
Rhea-AI Filing Summary
Recursion Pharmaceuticals, Inc. director Blake Borgeson reported selling 30,000 shares of Class A Common Stock on August 4, 2026 at $3.25 per share in an open-market or private transaction pursuant to a Rule 10b5-1 trading plan adopted on August 31, 2025, and now directly holds 6,188,287 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 30,000 shares
Net Sell
1 txn
Insider
Borgeson Blake
Role
Director
Sold
30,000 shs ($98K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock F1 | 30,000 | $3.25 | $98K |
Holdings After Transaction:
Class A Common Stock — 6,188,287 shares (Direct)
Footnotes (1)
- F1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.
Key Figures
Shares sold: 30,000 shares
Sale price: $3.25 per share
Shares held after sale: 6,188,287 shares
+1 more
4 metrics
Shares sold
30,000 shares
Class A Common Stock sold on August 4, 2026
Sale price
$3.25 per share
Price per share for Class A Common Stock sale
Shares held after sale
6,188,287 shares
Direct holdings of Blake Borgeson following the transaction
10b5-1 plan adoption date
August 31, 2025
Date Blake Borgeson adopted the Rule 10b5-1 trading plan
Key Terms
Rule 10b5-1 trading plan, Class A Common Stock, open market or private transaction
3 terms
Rule 10b5-1 trading plan regulatory
"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Class A Common Stock financial
"security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
open market or private transaction market
"transaction_code_description: Sale in open market or private transaction"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did RXRX disclose for Blake Borgeson?
Blake Borgeson, a director of Recursion Pharmaceuticals (RXRX), sold 30,000 shares of Class A Common Stock at $3.25 per share on August 4, 2026. The transaction was an open-market or private sale executed under a pre-arranged Rule 10b5-1 trading plan.
Was the RXRX insider sale made under a Rule 10b5-1 trading plan?
Yes. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Blake Borgeson on August 31, 2025. The filing also affirms the Rule 10b5-1 checkbox, indicating this transaction followed a pre-arranged trading plan rather than discretionary market timing.
What type of security was involved in Blake Borgeson’s RXRX trade?
The transaction involved Class A Common Stock of Recursion Pharmaceuticals. Borgeson sold 30,000 shares of this class at a price of $3.25 per share in an open-market or private transaction, as described in the Form 4’s non-derivative transaction table.
Did the latest RXRX Form 4 report any derivative securities activity?
No derivative securities activity was reported. The Form 4 lists zero derivative transactions, and the derivative summary section is empty. All reported activity relates solely to non-derivative Class A Common Stock sold on August 4, 2026 by director Blake Borgeson.